Mayo Clinic has launched Precure Research, an initiative built to study the earliest biological changes in disease, well before symptoms show up. The program focuses on conditions including Alzheimer's disease, heart failure, pulmonary fibrosis, chronic liver disease and chronic kidney disease. Its premise is that by the time a disease is diagnosed, it may have been developing quietly for years, leaving traces in proteins, metabolism, immune responses and environmental exposures that were hard to measure until recently.
The initiative pulls together genes, proteins, metabolites, clinical records, wearable devices, artificial intelligence and data on environmental exposures. According to the source, Mayo Clinic scientists have already identified inherited risks for cancer and cardiovascular disease in nearly 2,000 people, many of whom had no prior sign they were at risk. The article also notes that subtle biological changes linked to Alzheimer's disease can begin decades before memory loss, and that researchers have shown AI can help spot signs of pancreatic cancer years before diagnosis.
A central piece of the effort is building what Mayo describes as its largest integrated collection of biospecimens and health data. Biological samples are meant to become data, and data to become insight into disease mechanisms, which in turn could guide new biomarkers, therapies and more targeted clinical trials. The program also looks at the exposome, the cumulative effect of factors such as air, water, diet, pollutants, physical activity, sleep and stress. Researchers can now measure some of these exposures directly in blood, with early work focused on heavy metals, pesticides and microplastics.
Konstantinos Lazaridis, director of Precure Research, frames the work as a way to understand why disease develops in one person and not another. The stated long-term goal is to extend healthspan, meaning the years people live in good health, by addressing the drivers of chronic disease. The source describes this as part of Mayo Clinic's broader strategy, though the article does not report results for patients yet, and most of the discoveries it cites are early-stage findings.